Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials
- PMID:22055895
- DOI: 10.1016/j.smrv.2011.09.001
Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials
Abstract
Objectives: Gamma-hydroxybutyrate (GHB) is currently authorized by the European Medicines Agency (EMA) to treat narcolepsy with cataplexy in adults, and by the Food and Drug Administration (FDA) to treat cataplexy in patients with narcolepsy, with an expanded indication for the treatment of excessive daytime sleepiness. This study meta-analyses and reviews the effectiveness of GHB on the clinical features of narcolepsy and its neurophysiological correlates.
Methods: A systematic review of the literature using Medline, Embase, Web of Science, Cochrane reviews, clinical-trials.gov, Scopus, Scirus, and a subsequent meta-analysis were performed. Considered outcomes were: cataplexy attacks, subjective daytime sleepiness, sleep attacks, clinical global impression change (CGI-c), quality of life (QoL), hypnagogic hallucinations, sleep paralysis, mean sleep latencies on the multiple sleep latency test (MSLT) and maintenance of wakefulness test (MWT), nocturnal polysomnographic data.
Results: Nine randomized controlled trials reporting data on the effectiveness of GHB on narcolepsy were identified, for a total of 1,154 patients (771 patients in the GHB-treated group and 383 in the placebo group). The meta-analysis showed that GHB reduced cataplexy attacks both on a daily (weighted mean difference (WMD) -1.10; 95% confidence interval (CI) -1.29/-0.90, p < 0.00001) and a weekly basis (WMD -7.04; 95% CI -12.45/-1.63, p = 0.01), subjective nocturnal awakenings (WMD -1.33; 95% CI -1.78/-0.88, p < 0.00001), daytime sleep attacks on a weekly basis (WMD -9.30; 95% CI -15.92/-2.68, p = 0.006), subjective daytime sleepiness (WMD -2.81; 95% CI -4.13/-1.49, p < 0.0001) and sleep stage shifts (WMD -9.69; 95% CI -17.14/-2.24, p = 0.01). GHB increased sleep stages 3 + 4 (WMD 4.11; 95% CI 0.07/8.16, p = 0.05) and improved the CGI-c score (odds ratio (OR) 3.45; 95% CI 2.47/4.80, p < 0.00001). No significant changes were observed in night sleep latency, total sleep time, rapid-eye movement (REM) sleep and sleep stages 1 and 2.
Conclusions: This meta-analysis demonstrates the effectiveness of GHB in treating major, clinically relevant narcolepsy symptoms and sleep architecture abnormalities.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis.Xu XM, Wei YD, Liu Y, Li ZX.Xu XM, et al.Sleep Med. 2019 Dec;64:62-70. doi: 10.1016/j.sleep.2019.06.017. Epub 2019 Jul 6.Sleep Med. 2019.PMID:31671326
- Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.Scrima L, Hartman PG, Johnson FH Jr, Hiller FC.Scrima L, et al.Biol Psychiatry. 1989 Aug;26(4):331-43. doi: 10.1016/0006-3223(89)90048-6.Biol Psychiatry. 1989.PMID:2669980Clinical Trial.
- The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study.Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC.Scrima L, et al.Sleep. 1990 Dec;13(6):479-90. doi: 10.1093/sleep/13.6.479.Sleep. 1990.PMID:2281247Clinical Trial.
- An evaluation of sodium oxybate as a treatment option for narcolepsy.Abad VC.Abad VC.Expert Opin Pharmacother. 2019 Jul;20(10):1189-1199. doi: 10.1080/14656566.2019.1617273. Epub 2019 May 28.Expert Opin Pharmacother. 2019.PMID:31136215Review.
- Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS.Alshaikh MK, et al.J Clin Sleep Med. 2012 Aug 15;8(4):451-8. doi: 10.5664/jcsm.2048.J Clin Sleep Med. 2012.PMID:22893778Free PMC article.Review.
Cited by
- Narcolepsy: neural mechanisms of sleepiness and cataplexy.Burgess CR, Scammell TE.Burgess CR, et al.J Neurosci. 2012 Sep 5;32(36):12305-11. doi: 10.1523/JNEUROSCI.2630-12.2012.J Neurosci. 2012.PMID:22956821Free PMC article.Review.No abstract available.
- Homeostatic regulation through GABA and acetylcholine muscarinic receptors of motor trigeminal neurons following sleep deprivation.Toossi H, Del Cid-Pellitero E, Jones BE.Toossi H, et al.Brain Struct Funct. 2017 Sep;222(7):3163-3178. doi: 10.1007/s00429-017-1392-4. Epub 2017 Mar 15.Brain Struct Funct. 2017.PMID:28299422Free PMC article.
- Metabolic Alterations Associated with γ-Hydroxybutyric Acid and the Potential of Metabolites as Biomarkers of Its Exposure.Jung S, Kim S, Seo Y, Lee S.Jung S, et al.Metabolites. 2021 Feb 10;11(2):101. doi: 10.3390/metabo11020101.Metabolites. 2021.PMID:33578991Free PMC article.Review.
- Effect of Repeated Administration of ɣ-Valerolactone (GVL) and GHB in the Mouse: Neuroadaptive Changes of the GHB and GABAergic System.Frisoni P, Corli G, Bilel S, Tirri M, Gasparini LC, Alfieri L, Neri M, De-Giorgio F, Marti M.Frisoni P, et al.Pharmaceuticals (Basel). 2023 Aug 30;16(9):1225. doi: 10.3390/ph16091225.Pharmaceuticals (Basel). 2023.PMID:37765033Free PMC article.
- GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.Black SW, Morairty SR, Chen TM, Leung AK, Wisor JP, Yamanaka A, Kilduff TS.Black SW, et al.J Neurosci. 2014 May 7;34(19):6485-94. doi: 10.1523/JNEUROSCI.0080-14.2014.J Neurosci. 2014.PMID:24806675Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials